GRCE
Financials
- Market Capitalization 44.6 M
- Employee 5
- Founded 2002
- CEO N/A
- Website www.gracetx.com
- Headquarter Delaware, United States
- FIGI BBG001NMDXS6
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 4302 |  TVGN Tevogen Bio Holdings Inc. - Common Stock | 6.89 USD | +1.92% | +6.99% | +12.58% | +657.14% | 44.86 M USD | ||
| 4303 |  VERU Veru Inc. - Common Stock | 2.63 USD | -4.01% | -0.38% | +19.00% | +10.04% | 44.84 M USD | ||
| 4305 |  EDSA Edesa Biotech, Inc. - Common Shares | 4.62 USD | +0.43% | +3.82% | -12.67% | +92.50% | 44.54 M USD | ||
| 4327 |  KPTI Karyopharm Therapeutics Inc. - Common Stock | 1.87 USD | -3.61% | -4.10% | -73.21% | -80.60% | 42.41 M USD |
Frequently asked questions about Grace Therapeutics, Inc. Common Stock
What is the Grace Therapeutics, Inc. Common Stock stock price today?
The current price of Grace Therapeutics, Inc. Common Stock (GRCE) is 2.12. Over the past 24 hours, the stock has changed by -1.85%. Follow the GRCE chart for real-time price dynamics.
What is the stock ticker of Grace Therapeutics, Inc. Common Stock?
Grace Therapeutics, Inc. Common Stock trades under the ticker GRCE. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Grace Therapeutics, Inc. Common Stock stock going up?
GRCE has changed by -4.93% over the last week, +3.92% over the last month, and -46.73% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Grace Therapeutics, Inc. Common Stock?
Grace Therapeutics, Inc. Common Stock currently has a market capitalization of 44.6 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Grace Therapeutics, Inc. Common Stock earnings last quarter?
Last quarter, Grace Therapeutics, Inc. Common Stock reported earnings of -0.91 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Grace Therapeutics, Inc. Common Stock revenue for the last quarter?
Grace Therapeutics, Inc. Common Stock reported quarterly revenue of 14 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Grace Therapeutics, Inc. Common Stock net income for the last quarter?
Grace Therapeutics, Inc. Common Stock reported net income of -15.79 M for the last quarter. The previous quarter showed -1.18 M, which means net income changed by -1240.41%.
How many employees does Grace Therapeutics, Inc. Common Stock have?
As of the latest available data, Grace Therapeutics, Inc. Common Stock has 5 employees. Workforce size can provide additional context about the company's scale and operations.
What is Grace Therapeutics, Inc. Common Stock EBITDA?
Grace Therapeutics, Inc. Common Stock EBITDA is -15.2 M, and its EBITDA margin is -108.6 K%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Grace Therapeutics, Inc. Common Stock stock?
You can buy Grace Therapeutics, Inc. Common Stock (GRCE) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Grace Therapeutics, Inc. Common Stock stock?
Investing in Grace Therapeutics, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the GRCE chart and related analysis on metatrader.com as part of your research.